Package Leaflet: Information for the User
Tertensif retard 1.5 mg prolonged-release tablets
Indapamide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Tertensif retard 1.5 mg comes in the form of a prolonged-release tablet that contains indapamide as the active substance.
This medicine is used to lower high blood pressure in adults.
Indapamide is a diuretic. Most diuretics increase the amount of urine produced by the kidneys. However, indapamide is different from other diuretics, as it only produces a slight increase in the amount of urine formed.
In addition, indapamide dilates blood vessels so that blood can circulate more easily. This helps to reduce blood pressure.
Do not take Tertensif retard 1.5 mg:
Warnings and precautions:
Consult your doctor or pharmacist before starting to take Tertensif retard 1.5 mg:
You should inform your doctor if you have had photosensitivity reactions.
Your doctor may prescribe blood tests to check if you have low sodium or potassium levels, or high calcium levels.
If you think any of the above situations may apply to you, or if you have any doubts about taking this medicine, consult your doctor or pharmacist.
Use in athletes:
This medicine contains indapamide, which may produce a positive result in doping tests.
Using Tertensif retard 1.5 mg with other medicines:
Tell your doctor or pharmacist if you are using or have recently used or might use any other medicines.
Do not take Tertensif retard 1.5 mg with lithium (used to treat depression) due to the risk of increased lithium levels in the blood.
Make sure to inform your doctor if you are using any of the following medicines, as special care may be required:
Pregnancy and breastfeeding:
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
This medicine is not recommended during pregnancy. When pregnancy is planned or confirmed, a switch to an alternative treatment should be made as soon as possible. Inform your doctor if you are pregnant or wish to become pregnant.
The active substance is excreted in breast milk. If you are taking this medicine, breastfeeding is not recommended.
Driving and using machines:
This medicine may cause side effects due to the lowering of blood pressure, such as dizziness or fatigue (see section 4). The occurrence of these side effects is more likely after starting treatment and after dose increases. If this happens, you should avoid driving or performing other activities that require a state of alertness. However, when there is good control, these effects are unlikely.
Tertensif retard 1.5 mg contains lactose monohydrate.
If your doctor has told you that you have an intolerance to some sugars, inform your doctor before taking this medicine.
Take this medicine exactly as your doctor has told you. If you are unsure, consult your doctor or pharmacist.
The recommended dose is one tablet per day, preferably in the morning. The tablets can be taken with or without food.
The tablets should be swallowed whole with a glass of water. Do not break or chew them.
Treatment for high blood pressure is usually for life.
If you take more Tertensif retard 1.5 mg than you should:
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount ingested.
A very high dose of Tertensif retard 1.5 mg could cause nausea, vomiting, low blood pressure, cramps, dizziness, drowsiness, confusion, and changes in the amount of urine produced by the kidneys.
If you forget to take Tertensif retard 1.5 mg:
If you forget to take a dose of Tertensif retard 1.5 mg, take the next dose at the usual time. Do not take a double dose to make up for forgotten doses.
If you stop taking Tertensif retard 1.5 mg:
Since treatment for high blood pressure is usually for life, you should talk to your doctor before stopping this medicine.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking this medicine and contact your doctor immediately if you experience any of the following serious side effects:
In decreasing order of frequency, other side effects may be:
Frequent (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Very rare (may affect up to 1 in 10,000 people):
Frequency not known (cannot be estimated from the available data):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system included in Appendix V*. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date, EXP.: that appears on the packaging and on the blister. The expiry date is the last day of the month indicated.
Store below 30°C.
Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Tertensif retard 1.5 mg
The active substance is indapamide. Each tablet contains 1.5 mg of indapamide.
The other ingredients are:
Appearance of the product and pack contents
This medicine is a white, round, prolonged-release tablet.
The tablets are available in blisters of 10, 14, 15, 20, 30, 50, 60, 90, or 100 tablets, packaged in a cardboard box. Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex - France
Manufacturers:
Les Laboratoires Servier Industrie
905 route de Saran
45520 Gidy
FRANCE
and
Servier (Ireland) Industries Ltd
Gorey Road
Co. Wicklow - Arklow
IRELAND
and
ANPHARM Przedsiebiorstwo Farmaceutyczne S.A.
Ul. Annopol 6B - 03-236 Warszawa
POLAND
Manufacturer responsible for batch release (only for the Spanish market):
Laboratorios Servier, S.L.
Avda. de los Madroños 33
28043 – Madrid
SPAIN
Manufacturer responsible for batch release:
Delpharm Bretigny
Usine du Petit Paris
91220 Bretigny sur Orge
FRANCE
This medicine is authorized in the Member States of the European Economic Area under the following names:
Austria FLUDEX RETARD 1.5 mg
Belgium FLUDEX 1.5 mg
Cyprus FLUDEX 1.5 mg
Denmark NATRILIX RETARD
Estonia TERTENSIF SR
Finland NATRILIX RETARD 1.5 mg
France FLUDEX 1.5 mg
Germany NATRILIX SR 1.5 mg
Greece FLUDEX 1.5 mg
Hungary PRETANIX
Ireland NATRILIX SR
Italy NATRILIX LP 1.5 mg
Latvia TERTENSIF SR
Lithuania TERTENSIF SR
Luxembourg FLUDEX 1.5 mg
Malta NATRILIX SR
Netherlands FLUDEX SR 1.5 mg
Portugal FLUDEX LP
Slovakia TERTENSIF SR
Slovenia TERTENSIF SR
Spain TERTENSIF RETARD 1.5 mg
United Kingdom NATRILIX SR
(Northern Ireland)
Date of last revision of this leaflet: October 2021
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.